HOLLISTON, Mass., Aug. 8, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB:BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced the appointment of Joseph Damasio as the company's new Chief Financial Officer.
Read more at prnewswire.comBiostage Announces Appointment of New Chief Financial Officer
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Bundle%20of%20optical%20fiber%20cables%20with%20lights%20by%20volff%20via%20Adobe%20Stock.jpeg)
